Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Rhea-AI Summary

Relay Therapeutics (Nasdaq: RLAY) announced plans to release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. The company specializes in precision medicine, leveraging advanced computational and experimental technologies to enhance drug discovery. Notably, Relay Therapeutics utilizes its Dynamo™ platform to target challenging protein structures, focusing on therapies for oncology and genetic diseases. A teleconference will not be held alongside this press release.

CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter and full year 2021 financial results and corporate highlights after the close of market on Thursday, February 24, 2022. The company will not be conducting a teleconference in conjunction with its financial results press release.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. Relay Therapeutics is the first of a new breed of biotech created at the intersection of disparate technologies. Relay Therapeutics’ Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

Contact:
Hannah Mae Bohn
617-370-8814
hbohn@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com

 

FAQ

When will Relay Therapeutics report its Q4 2021 financial results?

Relay Therapeutics will report its Q4 2021 financial results on February 24, 2022, after market close.

Will there be a conference call after the Q4 2021 results announcement?

No, Relay Therapeutics will not conduct a teleconference following the financial results press release.

What technologies does Relay Therapeutics use in drug discovery?

Relay Therapeutics combines computational and experimental technologies, primarily through its Dynamo™ platform, to enhance drug discovery.

What areas is Relay Therapeutics focusing on?

Relay Therapeutics focuses on developing small molecule therapies for targeted oncology and genetic disease indications.